Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 17-valerate, Betamethasone
2. Betamethasone 17 Valerate
3. Betamethasone 17-valerate
4. Betnovate
5. Flubenisolonvalerate
6. Valerate, Betamethasone
1. Betamethasone 17-valerate
2. 2152-44-5
3. Betnovate
4. Betaderm
5. Luxiq
6. Beta-val
7. Betatrex
8. Tokuderm
9. Valnac
10. Betamethasone-17-valerate
11. Celestoderm
12. Bedermin
13. Bextasol
14. Stanoval
15. Rinderon V
16. Dermovaleas
17. Betneval
18. Dermosol
19. Beta-methasone 17-valerate
20. Ecoval 70
21. Betamethasone 17a-valerate
22. Betamethasone (as Valerate)
23. 9ifa5xm7r2
24. Chebi:31277
25. Betamethasone Valerate (betnovate)
26. Nsc-755912
27. [(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Pentanoate
28. Betnovateat
29. Celeston Valerate
30. 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17-valerate
31. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17-valerate
32. 9-fluoro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl Pentanoate
33. 9-fluoro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl Valerate
34. Topagen (veterinary)
35. Gentocin (veterinary)
36. Betamethasone Valerate (betamethasone 17-valerate)
37. Bettamousse
38. Betaval
39. Fuciderm
40. Betoid
41. Celestoderm V
42. Celestoderm-v
43. Betnesol V
44. Betnesol-v
45. Celestan V
46. Celestan-v
47. Celestane V
48. Ncgc00274064-01
49. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11.beta.,16.beta.)-
50. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(1-oxopentyl)oxy]-, (11.beta.,16.beta.)-
51. Einecs 218-439-3
52. Betamethasoni Valeras
53. Rinderon-v (tn)
54. Betamethasone-valerate
55. Luxiq (tn)
56. Topagen (salt/mix)
57. Beta-val (tn)
58. Betatrex (salt/mix)
59. Gentocin (salt/mix)
60. Chlorophytum Borivilanum
61. Betamethason-17-valerate
62. Dsstox_cid_2673
63. Unii-9ifa5xm7r2
64. Schembl7270
65. Chembl1497
66. Dsstox_rid_76684
67. Dsstox_gsid_22673
68. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11beta,16beta)-
69. Betamethasone 17alpha-valerate
70. Dtxsid7022673
71. Hy-b0727
72. Zinc3882052
73. Betamethasone Valerate (jp17/usp)
74. Betamethasone Valerate [jan]
75. Tox21_302288
76. Betamethasone Valerate [usan]
77. S1690
78. Betamethasone Valerate [vandf]
79. Akos015994704
80. Betamethasone Valerate [mart.]
81. Betamethasone Valerate [usp-rs]
82. Betamethasone Valerate [who-dd]
83. Betamethasone Valerate [who-ip]
84. Ccg-269509
85. Ks-1198
86. Nsc 755912
87. 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione-17-valerate
88. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-valerate
89. Betamethasone 17-valerate [mi]
90. Betamethasone Valerate [usan:usp:jan]
91. Ncgc00255185-01
92. (11beta,16beta)-9-fluoro-11,21-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Pentanoate
93. (2s,10s,11s,13s,15s,17s,1r,14r)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13, 15-trimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl Pe Ntanoate
94. Betamethasone Valerate [green Book]
95. Cas-2152-44-5
96. Betamethasone Valerate [orange Book]
97. Betamethasone Valerate [ep Monograph]
98. Betamethasone Valerate For System Suitability
99. Betamethasoni Valeras [who-ip Latin]
100. Cs-0009628
101. Betamethasone Valerate [usp Monograph]
102. D01357
103. Ab01274710-01
104. Ab01274710_02
105. 152m445
106. A815447
107. Q6445931
108. Betamethasone 17a-valerate 100 Microg/ml In Methanol
109. Brd-k34032314-001-04-1
110. (11.beta.,16.beta.)-9.alpha.-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17.alpha.-valerate
111. (8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Pentanoate
112. 9-fluoro-11.beta.,21-dihydroxy-16.beta.-methyl-3,20-dioxopregna-1,4-dien-17-yl Pentanoate #
| Molecular Weight | 476.6 g/mol |
|---|---|
| Molecular Formula | C27H37FO6 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Exact Mass | 476.25741706 g/mol |
| Monoisotopic Mass | 476.25741706 g/mol |
| Topological Polar Surface Area | 101 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 957 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Betamethasone valerate |
| PubMed Health | Betamethasone Valerate (On the skin) |
| Drug Classes | Corticosteroid, Intermediate |
| Drug Label | Luxq Foam contains betamethasone valerate, USP, a synthetic corticosteroid, for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory agents.Betamethasone valerate is 9-... |
| Active Ingredient | Betamethasone valerate |
| Dosage Form | Lotion; Ointment; Cream; Aerosol, foam |
| Route | Topical |
| Strength | 0.12%; eq 0.1% base |
| Market Status | Prescription |
| Company | Sti Pharma; Actavis Mid Atlantic; Perrigo; Fougera |
| 2 of 2 | |
|---|---|
| Drug Name | Betamethasone valerate |
| PubMed Health | Betamethasone Valerate (On the skin) |
| Drug Classes | Corticosteroid, Intermediate |
| Drug Label | Luxq Foam contains betamethasone valerate, USP, a synthetic corticosteroid, for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory agents.Betamethasone valerate is 9-... |
| Active Ingredient | Betamethasone valerate |
| Dosage Form | Lotion; Ointment; Cream; Aerosol, foam |
| Route | Topical |
| Strength | 0.12%; eq 0.1% base |
| Market Status | Prescription |
| Company | Sti Pharma; Actavis Mid Atlantic; Perrigo; Fougera |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-01
Pay. Date : 2014-04-29
DMF Number : 22062
Submission : 2008-10-07
Status : Active
Type : II
Axplora is your partner of choice for complex APIs.
GDUFA
DMF Review : Complete
Rev. Date : 2018-08-14
Pay. Date : 2018-07-09
DMF Number : 12749
Submission : 1997-11-18
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-29
Pay. Date : 2014-05-21
DMF Number : 4118
Submission : 1981-04-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3105
Submission : 1978-01-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5863
Submission : 1985-05-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5554
Submission : 1984-10-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4578
Submission : 1982-06-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4397
Submission : 1981-12-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6405
Submission : 1986-06-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5465
Submission : 1984-07-20
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CREAM;TOPICAL - EQ 0.1% BASE
USFDA APPLICATION NUMBER - 18861
DOSAGE - OINTMENT;TOPICAL - EQ 0.1% BASE
USFDA APPLICATION NUMBER - 18865
DOSAGE - LOTION;TOPICAL - EQ 0.1% BASE
USFDA APPLICATION NUMBER - 18866
DOSAGE - AEROSOL, FOAM;TOPICAL - 0.12%
USFDA APPLICATION NUMBER - 20934
Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Thickeners and Stabilizers
Controlled & Modified Release
Emulsifying Agents
Film Formers & Plasticizers
Surfactant & Foaming Agents
Granulation
Lubricants & Glidants
Parenteral
Direct Compression
Rheology Modifiers
Coating Systems & Additives
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
55
PharmaCompass offers a list of Betamethasone Valerate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betamethasone Valerate manufacturer or Betamethasone Valerate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betamethasone Valerate manufacturer or Betamethasone Valerate supplier.
PharmaCompass also assists you with knowing the Betamethasone Valerate API Price utilized in the formulation of products. Betamethasone Valerate API Price is not always fixed or binding as the Betamethasone Valerate Price is obtained through a variety of data sources. The Betamethasone Valerate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A BETA-VAL manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BETA-VAL, including repackagers and relabelers. The FDA regulates BETA-VAL manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BETA-VAL API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of BETA-VAL manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A BETA-VAL supplier is an individual or a company that provides BETA-VAL active pharmaceutical ingredient (API) or BETA-VAL finished formulations upon request. The BETA-VAL suppliers may include BETA-VAL API manufacturers, exporters, distributors and traders.
click here to find a list of BETA-VAL suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A BETA-VAL DMF (Drug Master File) is a document detailing the whole manufacturing process of BETA-VAL active pharmaceutical ingredient (API) in detail. Different forms of BETA-VAL DMFs exist exist since differing nations have different regulations, such as BETA-VAL USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A BETA-VAL DMF submitted to regulatory agencies in the US is known as a USDMF. BETA-VAL USDMF includes data on BETA-VAL's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The BETA-VAL USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of BETA-VAL suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The BETA-VAL Drug Master File in Japan (BETA-VAL JDMF) empowers BETA-VAL API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the BETA-VAL JDMF during the approval evaluation for pharmaceutical products. At the time of BETA-VAL JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of BETA-VAL suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a BETA-VAL Drug Master File in Korea (BETA-VAL KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of BETA-VAL. The MFDS reviews the BETA-VAL KDMF as part of the drug registration process and uses the information provided in the BETA-VAL KDMF to evaluate the safety and efficacy of the drug.
After submitting a BETA-VAL KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their BETA-VAL API can apply through the Korea Drug Master File (KDMF).
click here to find a list of BETA-VAL suppliers with KDMF on PharmaCompass.
A BETA-VAL CEP of the European Pharmacopoeia monograph is often referred to as a BETA-VAL Certificate of Suitability (COS). The purpose of a BETA-VAL CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of BETA-VAL EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of BETA-VAL to their clients by showing that a BETA-VAL CEP has been issued for it. The manufacturer submits a BETA-VAL CEP (COS) as part of the market authorization procedure, and it takes on the role of a BETA-VAL CEP holder for the record. Additionally, the data presented in the BETA-VAL CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the BETA-VAL DMF.
A BETA-VAL CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. BETA-VAL CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of BETA-VAL suppliers with CEP (COS) on PharmaCompass.
A BETA-VAL written confirmation (BETA-VAL WC) is an official document issued by a regulatory agency to a BETA-VAL manufacturer, verifying that the manufacturing facility of a BETA-VAL active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting BETA-VAL APIs or BETA-VAL finished pharmaceutical products to another nation, regulatory agencies frequently require a BETA-VAL WC (written confirmation) as part of the regulatory process.
click here to find a list of BETA-VAL suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing BETA-VAL as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for BETA-VAL API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture BETA-VAL as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain BETA-VAL and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a BETA-VAL NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of BETA-VAL suppliers with NDC on PharmaCompass.
BETA-VAL Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of BETA-VAL GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right BETA-VAL GMP manufacturer or BETA-VAL GMP API supplier for your needs.
A BETA-VAL CoA (Certificate of Analysis) is a formal document that attests to BETA-VAL's compliance with BETA-VAL specifications and serves as a tool for batch-level quality control.
BETA-VAL CoA mostly includes findings from lab analyses of a specific batch. For each BETA-VAL CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
BETA-VAL may be tested according to a variety of international standards, such as European Pharmacopoeia (BETA-VAL EP), BETA-VAL JP (Japanese Pharmacopeia) and the US Pharmacopoeia (BETA-VAL USP).
